RECRUITING

Intermittent Hypoxia in Persons With Multiple Sclerosis

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.

Official Title

Intermittent Hypoxia Initiated Motor Plasticity in Individuals With Multiple Sclerosis

Quick Facts

Study Start:2024-04-30
Study Completion:2027-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06276634

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnoses of relapsing form of MS (including relapsing-remitting MS and secondary-progressive MS)
  2. * Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5
  3. * Motor Functional System Scale (FSS) between 2-4
  4. * Relapse free for at least 1 year
  5. * Age ≥ 18 years and ≤ 75 years
  6. * Safe to be scanned based on MRI questionnaire
  7. * Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening
  1. * Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive of acute cerebrovascular disease on baseline MRI scan
  2. * Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55)
  3. * History of epilepsy
  4. * Chronic obstructive pulmonary disease
  5. * Uncontrolled Sleep apnea
  6. * Pregnancy

Contacts and Locations

Study Contact

Alexander Barry, MS, CCRC
CONTACT
3122381435
abarry@sralab.org

Principal Investigator

Milap Sandhu, Pt, PhD
PRINCIPAL_INVESTIGATOR
Shirley Ryan AbilityLab

Study Locations (Sites)

Shirley Ryan AbilityLab
Chicago, Illinois, 60611
United States

Collaborators and Investigators

Sponsor: Shirley Ryan AbilityLab

  • Milap Sandhu, Pt, PhD, PRINCIPAL_INVESTIGATOR, Shirley Ryan AbilityLab

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-30
Study Completion Date2027-01

Study Record Updates

Study Start Date2024-04-30
Study Completion Date2027-01

Terms related to this study

Keywords Provided by Researchers

  • multiple sclerosis
  • AIH
  • Hypoxia

Additional Relevant MeSH Terms

  • Multiple Sclerosis
  • Multiple Sclerosis-Relapsing-Remitting
  • Multiple Sclerosis, Secondary Progressive